A more accurate detection of codon 72 polymorphism and LOH of the TP53 gene

Cancer Letters

Volumn 189, Issue 1, 2003, Pages 91-96

  Baccouche, Sami ^a   Mabrouk, Imed ^b   Said, Salem ^b   Mosbah, Ali ^c   Jlidi, Rachid ^d   Gargouri, Ali ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^b UNIVERSITY OF SOUSSE   (Tunisia)

^c SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^d HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

Codon 72; Loss of heterozygosity; Polymerase chain reaction; Polymorphism; TP53

Indexed keywords

GENOMIC DNA; RESTRICTION ENDONUCLEASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA EXTRACTION; EXON; GENE AMPLIFICATION; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL;

DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA MUTATIONAL ANALYSIS; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY;

EID: 0037427560     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00405-6     Document Type: Article

References (24)

1. Raycroft L., Wu H., Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 249:1990;1049-1051.
2. Marx J., Momand J., Finlay C.A. How p53 suppresses cell growth. Science. 262:1993;1644-1645.
3. Nigro J.M., Barker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-708.
4. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:1993;523-526.
5. Harris C.C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 262:1993;1980-1981.
6. Ara S., Lee P.S.Y., Hansen M.F., Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 18:1990;4961.
7. Delacalle-Martin O., Fabregat V., Romero M., Soler J., Vives J., Yague J. Acc II polymorphism of the p53 gene. Nucleic Acids Res. 18:1990;4963.
8. Olschwang S., Laurentpuig P., Vassal A., Salmon R.J., Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum. Genet. 86:1991;369-370.
9. Oka K., Ishkawa J., Bruner J.M., Takahashi R., Saya H. Detection of loss of heterozygosity in the p53 gene in renal cell carcinoma and bladder cancer using the polymerase chain reaction. Mol. Carcinog. 4:1991;10-13.
10. Soulitzis N., Sourvinos G., Dokianakis D., Spandidos D.A. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 179:2002;175-183.
11. Rong F., Ming-Tsang, David M., John C.W., Karl T.K., John K.W., David C.C. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 9:2000;1037-1042.
12. Pierce L.M., Sivaraman L., Chang W., Lum Donlon A.T., Seifried A., Wilkens L.R., Lau A.F., Le Marchand L. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol. Biomarkers Prev. 9:2000;1199-1204.
13. Tenti P., Vesentini N., Spaudo M.R., Zappatore R., Migliora P., Carnevali L., Ranzani G.N. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from Northern Italy. Cancer Epidemiol. Biomarkers Prev. 9:2000;435-438.
14. O'Connor D.P., Kay E.W., Leader M., Atkins G.J., Murphy G.M., Mabruk M.F. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J. Clin. Pathol. 54:2001;539-542.
15. Madeleine M.M., Shera K., Schwartz S.M., Daling J.R., Galloway D.A., Wipf G.C., Carter J.J., McKnight B., McDougall J.K. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol. Biomarkers Prev. 9:2000;225-227.
16. Guimaraes D.P., Lu S.H., Snijder P., Wilmotte R., Herrero R., Lenoir G., Montesano R., Meijer C., Walboomers J., Hainaut P. Absence of association between HPV DNA, TP53 codon 72 polymorphism and risk of oesophageal cancer in a high-risk area of China. Cancer Lett. 162:2001;231-235.
17. Klug S.J., Wilmotte R., Santos C., Almonte M., Herro R., Guerrero I., Caceres E. TP53 polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiol. Biomarkers Prev. 10:2001;1009-1012.
18. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 19:1999;1092-1100.
19. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I.M., Matlashewski G., Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 393:1998;229-234.
20. Oka K., Ishkawa J., Bruner J.M., Takahashi R., Saya H. Detection of loss of heterozygosity in the p53 gene in renal cell carcinoma and bladder cancer using the polymerase chain reaction. Mol. Carcinog. 4:1991;10-13.
21. Bos J.L., Verlaan-de Vries A.M., Jansen A.M., Veeneman G.H., van Boom J.H., van der Eb A.J. Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. Nucleic Acids Res. 12:1984;9155-9163.
22. Suarez H.G. Activated oncogenes in human tumors. Anticancer Res. 9:1989;1331-1344.
23. Sambrook J., Fritsch E.F., Maniatis T. Isolation of high-molecular-weight DNA from mammalian cells. Molecular Cloning, A Laboratory Manual. 1989;. pp. 9-19.
24. Okada F., Shiraki T., Maekawa M., Sato S. A p53 polymorphism associated with increased risk of hepatitis C virus infection. Cancer Lett. 30:2001;137-142.